Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin, Cisplatin, and 5-FU in Advanced Gastric or Esophageal Adenocarcinoma
NCT00165191Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 1998
- Primary completion
- Jan 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of doxorubicin, cisplatin, fluorouracil in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by Dana-Farber Cancer Institute. Started Aug 1998; status: completed.
02
Drugs
doxorubicincisplatinfluorouracil
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00165191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165191.